Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk. (PubMed, Neurotherapeutics) - Aug 28, 2026 - "This study investigated associations between Medicare Part D prescription fills prior to PD diagnosis for 7 rTK inhibitors (erlotinib, sorafenib, pazopanib, imatinib, sunitinib, nintedanib, and dasatinib) and 4 nrTK inhibitors (nilotinib, ibrutinib, ruxolitinib, and tofacitinib) and PD risk. Given the chemotherapeutic mechanisms of these medications, and the known cancer-PD inverse relationship, we performed a sensitivity analysis adjusting for relevant cancer subtypes, yielding a similar inverse association. Overall, the use of rTK and nrTK inhibitors was associated with a lower risk of developing PD, although there may be differential impact of this medication class depending on specific inhibition pathways."
Journal • CNS Disorders • Movement Disorders • Oncology • Parkinson's Disease
|
|
Brad A Racette; Giovanni R Malaty; Jordan A Killion; Osvaldo J Laurido-Soto; Sai Anmisha Doddamreddy
|